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The immunodominant 
myeloperoxidase T-cell epitope 
induces local cell-mediated 
injury in antimyeloperoxidase 
glomerulonephritis
Ooi et al., Proc Natl Acad Sci USA 2012; 109: E2615–E2624; doi:10.1073/
pnas.1210147109
The molecular basis of immunity to the target autoantigen 
myeloperoxidase (MPO) is crucial in understanding the patho-
genesis of anti-neutrophil cytoplasmic antibody (ANCA)-
related vasculitis. Recently, Ooi et al. sought to determine the 
potential role of CD4+ T cells in the effector immune response 
to specific MPO epitopes. Using a murine system, they defined 
relevant T-cell epitopes that recognized MPO in mice that had 
been immunized with MPO peptides. They identified one spe-
cific epitope (MPO409–428) that induced the strongest T-cell 
response. Autoreactivity against this peptide was associated 
with the human class II molecule HLA DRB*1501. Mice that 
were immunized with MPO409–428 developed classical focal 
necrotizing glomerulonephritis (GN) after MPO was depos-
ited in glomeruli. Irrespective of the peptide or MPO depo-
sition within glomeruli, antigen-specific CD4+ T cells were 
recruited into the glomerulus and produced necrotizing GN. 
Subsequently, the authors conjugated the MPO409–428 fragment 
to a monoclonal antibody, which localized this epitope to the 
glomerular basement membrane without producing injury 
itself. Following adoptive transfer of CD4+ T-cell clones with 
specificity to this epitope, severe GN developed in addition to 
production of anti-MPO antibodies, indicating the relevance 
of this epitope to the production of anti-MPO antibody. The 
authors were further able to identify the critical residues within 
MPO409–428 peptide that were responsible for immunity.
Taken together, these novel findings have defined the major 
immunodominant epitopes for MPO immunity and demon-
strated the role of CD4+ T cells in causing renal vasculitic lesions 
against autoantigens deposited in the kidney. These studies open 
the prospect of developing anticytokine therapies directed 
toward inhibiting CD4+ effector T-cell pathways as entirely new 
therapeutic options for ANCA-related renal vasculitis treatment.
P. Toby Coates
Anti-inflammatory activity of IgG1 
mediated by Fc galactosylation and 
association of FcgRIIB and dectin-1
Karsten et al., Nat Med 2012; 18: 1401–1406; doi:10.1038/nm.2862
Activating FcgR and the complement cascade promotes 
inflammatory responses in autoimmune diseases, such as 
glomerulonephritis, so it is important to elucidate regula-
tory cross-talk between these branches of the immune system. 
Recently, Karsten and colleagues showed a novel complement–
FcgR cross-talk. They used FcR g-chain-deficient mice, which 
express only the inhibitory IgG receptor FcgRIIB but no activat-
ing FcgR, and estimated C5a-mediated inflammatory responses 
both in vitro and in vivo. The FcR g-chain-deficient animals 
showed a decrease in immune complex-mediated neutrophil 
migration despite the presence of C5a receptor (C5aR). Treat-
ment with FcgRIIB-specific antibody abrogated the inhibitory 
effect of immune complex on C5a-mediated neutrophil migra-
tion. To search for potential new partners of FcgRIIB driving 
immunoreceptor tyrosine-based inhibition motif (ITIM) and 
Src homology 2 domain-containing inositol phosphatase (SHIP) 
phosphorylation at its downstream, the authors focused on dec-
tin-1, the C-type lectin-like receptor that harbors an immuno-
receptor tyrosine-based activation motif (ITAM)-like motif and 
is expressed on neutrophils. Studies using dectin-1-deficient 
mice showed that immune complex and FcgRIIB suppressed 
C5a-induced inflammation in a dectin-1-dependent manner. 
Ligation of dectin-1 results in the phosphorylation of spleen 
tyrosine kinase (Syk), and inducible knockout of Syk as well as 
pharmacological targeting of Syk by Syk kinase inhibitors com-
pletely reversed the inhibitory effect of immune complexes on 
C5a-mediated neutrophil chemotaxis. IgG molecules contained 
a branched N-glycan in their Fc portion, and the authors assessed 
the importance of N-glycan galactosylation using a highly galac-
tosylated form and a degalactosylated form of antibody. Immune 
complexes composed of a highly galactosylated form but not a 
degalactosylated form of antibody inhibited the C5a-mediated 
chemotaxis. Promotion of the association of FcgRIIB and dectin-1 
was directly demonstrated by Förster resonance energy transfer. 
Thus, N-glycan galactosylation drives the association of FcgRIIB 
and dectin-1, thereby inhibiting C5a-induced inflammation.
This study uncovered the mechanisms that modulate the 
actions of C5a, the key mediator of the complement cascade. 
High N-glycan galactosylation of IgG1 molecules promotes a 
cooperative signaling pathway that blocks the proinflammatory 
effector functions of C5aR. To gain new mechanistic insights into 
immune complex-mediated autoimmune diseases, it is essential 
to know complex cross-talk mechanisms between complement 
and other immune systems.
Masaomi Nangaku 
High Fc glycan galactosylation is crucial for the inhibitory effect of 
IgG1 immune complexes in vivo and promotes the association of 
FcgRIIB and dectin-1. Development of cutaneous lesions is shown. IC, 
immune complex.
Ka
rs
te
n 
et
 a
l./
N
at
 M
ed
Kidney International (2012) 82             1247
journal  c lub
Risk of coronary events in people 
with chronic kidney disease 
compared with those with diabetes: 
a population-level cohort study
Tonelli et al., Lancet 2012; 380: 807–814; doi:10.1016/S0140-
6736(12)60572-8
People with chronic kidney disease (CKD) have high rates 
of cardiovascular events, particularly when proteinuria is 
present. It is unknown, however, whether CKD constitutes 
a coronary heart disease (CHD) risk equivalent, compared 
with accepted criteria such as diabetes. The CHD risk equiva-
lent is defined as a 10-year risk of coronary death or myocar-
dial infarction (MI) that is equivalent to the risk associated 
with previous MI. Tonelli et al. addressed this question in an 
observational study, using a population-based cohort from 
Alberta, Canada. They assessed almost 1.3 million people with 
measures of estimated glomerular filtration rate (eGFR) and 
proteinuria. They defined baseline CKD as eGFR 15–59 ml/
min per 1.73 m2 (CKD stages 3–4). During a median follow-
up of 48 months, 1% of the participants experienced MI. The 
unadjusted rate of MI was highest in people with previous MI. 
In people without previous MI, the rate was lower in those 
with diabetes (without CKD) than in those with CKD (with-
out diabetes; Figure, top). The rate of incident MI in people 
with diabetes was substantially lower than that in people with 
CKD stage 3b and severe-degree proteinuria. However, after 
adjustment for age, sex, and comorbidities, the relative rate 
in people with CKD was lower than that in people with dia-
betes or previous MI. Finally, the proportion of participants 
who died within 30 days of admission for MI was significantly 
higher among people with CKD (but no diabetes or previous 
MI) than among those with diabetes but no CKD or previous 
MI or among those with a history of MI (Figure, bottom).
Although, strictly speaking, the analysis by Tonelli et al. does 
not support classification of CKD as a CHD risk equivalent, CKD 
should be added to the list of criteria defining patients at highest 
risk of future coronary events.
Tilman B. Drüeke
Dialysis dose scaled to body 
surface area and size-adjusted, 
sex-specific patient mortality
Ramirez et al., Clin J Am Soc Nephrol advance online publication, 13 
September 2012, doi:10.2215/CJN.00390112
Although the National Cooperative Dialysis Study helped 
define a minimal target dose for the amount of hemodialysis 
required for chronic kidney dialysis patients receiving thrice-
weekly hemodialysis treatments, simply increasing the ses-
sional single-pool urea clearance target (spKt/V) from 1.0 to 
1.2 to 1.4 has not been shown to improve patient outcomes. 
This could be due to many factors, including whether urea 
itself is a significant azotemic toxin or whether it reproduc-
ibly acts as a surrogate marker for other clinically significant 
azotemic toxins. An alternative explanation would be that 
the model used to calculate dosing for patients is inaccurate, 
given that in other branches of renal medicine, renal func-
tion is expressed as creatinine clearance and corrected for 
body surface area, rather than the volume of urea distribution. 
Thus, one of the conundrums for modern-day practice based 
on current spKt/V targets is that, compared with the gen-
eral population, women treated with hemodialysis generally 
have worse survival, whereas the morbidly obese have better 
survival. Although this may be confounded by the generally 
shorter dialysis sessions for women and longer sessions for 
the obese, another explanation would be that dosing based 
simply on body-water estimations leads to undertreatment 
of one group and greater treatment for the other. Thus, it is 
generally recognized that there are many flaws in the current 
spKt/V-based dialysis prescription, but the question arises 
of whether spKt/V can be sufficiently modified. Ramirez and 
colleagues reanalyzed the hemodialysis dose delivered after 
correcting spKt/V for body surface area and showed that, 
on the basis of standard spKt/V, women received a greater 
dialysis dosage than men, but after correction for body sur-
face area, women had actually received a lower dosage than 
men. Equally important was a dose–survival benefit up to 
an spKt/V of about 1.6–1.7, suggesting that not only should 
standard spKt/V targets be increased, but spKt/V should also 
be adjusted for body surface area.
Whether health-care purchasers would fund such prospective 
trials designed to optimize dialysis dosages remains debatable.
Andrew Davenport
Clinical outcomes in each risk group. Unadjusted rates and 95% 
confidence intervals of myocardial infarction (top) and all-cause 
mortality (bottom) per 1000 person-years. CKD is defined as eGFR less 
than 60 ml/min per 1.73 m2 with or without proteinuria.
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